Sunday, December 1, 2019

Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US

Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US Sun Pharma said the litigation had already been disclosed in the company#39;s FY19 annual report.

from Moneycontrol Business News https://ift.tt/2ODfudW

No comments:

Post a Comment

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...